Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 4, 2015Traverse Biosciences Also Grants Aratana Therapeutics the Exclusive Option to Sublicense TRB-N0224
Traverse Biosciences announced today that it has executed a $250,000 cooperative research and development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ: PETX) to advance the development...
-
May 1, 2015Conference Call and Webcast scheduled for May 8, 2015, 8:30 a.m. ET
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Apr 27, 2015ADXS31-164 (AT-014) in Combination with Palliative Radiation Delays Tumor Progression, Prolongs Overall Survival and Maintains Limb Function in Preliminary Data from a Clinical Study in Canine Osteosarcoma
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Apr 22, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 19, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 12, 2015-- Provides additional product updates --
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, announced...
-
Mar 11, 2015Conference Call and Webcast scheduled for March 13, 2015, 8:30 a.m. ET
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Mar 4, 2015
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 24, 2015Product is the first approved monoclonal antibody to aid in the treatment of canine B-cell lymphoma
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...
-
Feb 10, 2015Provides additional details on AT-001 pivotal efficacy study, announces two technical section complete letters for safety, provides manufacturing update for AT-004, and announces completion of enrollment for AT-005's T-CHOMP study
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals,...